START Midwest physician Nehal Lakhani, MD, PhD, authored an article that was recently published on The New England Journal of Medicine‘s website. The article titled “The Efficacy of Selpercatinib in RET-Altered Thyroid Cancers” details START Midwest’s former LIBRETTO-001 clinical trial, which concluded that “selpercatinib showed durable efficacy with mainly low-grade toxic effects in patients with medullary thyroid cancer with and without previous vandetanib or cabozantinib treatment.”
LIBRETTO-001 was one of the many Phase I clinical trials offered to patients through ’s START Midwest partnership Cancer and Hematology Centers of Western Michigan (CHC). To learn more about these clinical trials, visit our START Midwest Research page or CHC’s website.
START Midwest is part of START’s global network of Phase I clinical research sites. It is the largest Phase I oncology drug development program in Michigan and part of the largest Phase I oncology program in the world. It offers cancer patients access to cutting-edge clinical trial drugs, including immunotherapy and targeted therapy options.